Please use this identifier to cite or link to this item:
|Title:||Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials|
Janne, P. A.
Liang, Jane Q.
Mok, T. S. K.
Sbar, E. I.
Central Clinical School: Medicine
|Publisher:||Oxford University Press|
|Citation:||Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials, Annals of Oncology, vol.27, 3, 2016,pp 423-429|
|Department/Unit/Centre:||Central Clinical School: Medicine|
|Disclaimer:||This work has been made available to the staff and students of the University of Sydney for the purposes of research and study only. It constitutes material that is held by the University for the purposes of reporting for HERDC and the ERA. This work may not be downloaded, copied and distributed to any third party .|
|Type:||C1 - Refereed Journal articles|
|Appears in Collections:||University of Sydney Research Outputs|
Items in Sydney Research Online are protected by copyright, with all rights reserved, unless otherwise indicated.